Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGAVE-Pilot octreotide study in refractory GAVE with symptomatic gastrointestinal bleeding
2020-004075-41Phase 2Active
- Sponsor
- Radboudumc
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of octreotide in gastric antral vascular ectasia (GAVE) (2 arms), sponsored by Radboudumc. Primary endpoint: Successful response. Started Jan 2021; status: active.
02
Drugs
octreotide
03
Conditions
gastric antral vascular ectasia (GAVE)
Beyond the preview
Go deeper on 2020-004075-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004075-41.